ArticleAnnals of medicine2025
Propofol in combination with salvianolic acid A protect against lipopolysaccharide-induced cardiac dysfunction and ferroptosis through activating the SIRT1/FoxO1 signaling under diabetic condition.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Electroacupuncture (EA) promotes angiogenesis and ameliorates dysregulated autophagy in ischemic stroke mice by modulating the ELAVL1/SIRT1/FOXO1 pathway.Metabolic brain disease · 2026Article
- The role and mechanism of TNFRSF21 in promoting necroptosis of vascular endothelial cells and inducing vascular leakage in sepsis.Journal of molecular medicine (Berlin, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the therapeutic potential of a combined low-dose propofol (PPF) and salvianolic acid A (SAA) regimen in mitigating lipopolysaccharide (LPS)-induced cardiac dysfunction and ferroptosis in diabetic contexts, and to explore the role of the sirtuin 1 (SIRT1)/forkhead box O1 (FoxO1) signaling pathway.
methodsType 2 diabetes (DM) was induced in mice, followed by LPS administration to induce cardiac injury. The mice were randomly assigned to six groups: control, DM, control + LPS, DM + LPS, DM + LPS + high-dose PPF, and DM + LPS + low-dose PPF + SAA. Cardiac function was assessed
resultsDiabetes aggravated LPS-induced cardiac injury in mice evidenced as impaired myocardial function, which was concomitant with decreased cardiac expression of SIRT1, FoxO1, and GPX4 proteins; increased production of oxidative stress, pro-inflammatory cytokines, oxidized lipids, and damaged mitochondrial cristae as compared to NC + LPS group. The combined use of PPF and SAA enhanced cardiac SIRT1 and FoxO1 and ameliorated LPS-mediated cardiac dysfunction in diabetic mice, but these beneficial effects were abolished by inhibition of SIRT1 or FoxO1.
conclusionThe combination of low-dose PPF and SAA effectively protects against LPS-induced cardiac dysfunction and ferroptosis in diabetic conditions by activating the SIRT1/FoxO1 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.